Literature DB >> 26656116

Mucosal IgG Levels Correlate Better with Respiratory Syncytial Virus Load and Inflammation than Plasma IgG Levels.

Marloes Vissers1, Inge M L Ahout1, Marien I de Jonge1, Gerben Ferwerda2.   

Abstract

Maternal vaccination is currently considered a strategy against respiratory syncytial virus (RSV) infections. In RSV-infected infants, high mucosal IgG levels correlated better with reduced RSV load and lower mucosal CXCL10 levels than plasma IgG levels. For future vaccination strategies against RSV, more focus should be on the mucosal humoral immune response.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26656116      PMCID： PMC4783421          DOI： 10.1128/CVI.00590-15

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN： 1556-679X


  14 in total

1.  Recovery of cytopathogenic agent from chimpanzees with coryza.

Authors:  R E BLOUNT; J A MORRIS; R E SAVAGE
Journal:  Proc Soc Exp Biol Med       Date:  1956-07

2.  Neonatal Fc receptor for IgG regulates mucosal immune responses to luminal bacteria.

Authors:  Masaru Yoshida; Kanna Kobayashi; Timothy T Kuo; Lynn Bry; Jonathan N Glickman; Steven M Claypool; Arthur Kaser; Takashi Nagaishi; Darren E Higgins; Emiko Mizoguchi; Yoshio Wakatsuki; Derry C Roopenian; Atsushi Mizoguchi; Wayne I Lencer; Richard S Blumberg
Journal:  J Clin Invest       Date:  2006-08       Impact factor: 14.808

Review 3.  Mucosal delivery of vaccine antigens and its advantages in pediatrics.

Authors:  Maria Teresa De Magistris
Journal:  Adv Drug Deliv Rev       Date:  2006-03-03       Impact factor: 15.470

4.  Nasopharyngeal gene expression, a novel approach to study the course of respiratory syncytial virus infection.

Authors:  Corné H van den Kieboom; Inge M L Ahout; Aldert Zomer; Kim H Brand; Ronald de Groot; Gerben Ferwerda; Marien I de Jonge
Journal:  Eur Respir J       Date:  2014-09-26       Impact factor: 16.671

5.  Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.

Authors: 
Journal:  Pediatrics       Date:  1998-09       Impact factor: 7.124

6.  Rapid and sensitive method using multiplex real-time PCR for diagnosis of infections by influenza a and influenza B viruses, respiratory syncytial virus, and parainfluenza viruses 1, 2, 3, and 4.

Authors:  Kate E Templeton; Sitha A Scheltinga; Matthias F C Beersma; Aloys C M Kroes; Eric C J Claas
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

7.  Risk of primary infection and reinfection with respiratory syncytial virus.

Authors:  W P Glezen; L H Taber; A L Frank; J A Kasel
Journal:  Am J Dis Child       Date:  1986-06

8.  Maternal antibody and respiratory syncytial virus infection in infancy.

Authors:  M M Ogilvie; A S Vathenen; M Radford; J Codd; S Key
Journal:  J Med Virol       Date:  1981       Impact factor: 2.327

9.  Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level.

Authors:  W P Glezen; A Paredes; J E Allison; L H Taber; A L Frank
Journal:  J Pediatr       Date:  1981-05       Impact factor: 4.406

10.  Association of a new type of cytopathogenic myxovirus with infantile croup.

Authors:  R M CHANOCK
Journal:  J Exp Med       Date:  1956-10-01       Impact factor: 14.307
View more
  15 in total

1.  Antibody and B cell responses to an investigational adjuvanted RSV vaccine for older adults.

Authors:  Adriana Weinberg; Stacie L Lambert; Jennifer Canniff; Li Yu; Nancy Lang; Mark T Esser; Judith Falloon; Myron J Levin
Journal:  Hum Vaccin Immunother       Date:  2019-06-03       Impact factor: 3.452

Review 2.  Aberrant T cell immunity triggered by human Respiratory Syncytial Virus and human Metapneumovirus infection.

Authors:  Andrea E González; Margarita K Lay; Evelyn L Jara; Janyra A Espinoza; Roberto S Gómez; Jorge Soto; Claudia A Rivera; Katia Abarca; Susan M Bueno; Claudia A Riedel; Alexis M Kalergis
Journal:  Virulence       Date:  2016-12-02       Impact factor: 5.882

Review 3.  Establishing Correlates of Protection for Vaccine Development: Considerations for the Respiratory Syncytial Virus Vaccine Field.

Authors:  Prasad S Kulkarni; Julia L Hurwitz; Eric A F Simões; Pedro A Piedra
Journal:  Viral Immunol       Date:  2018-01-16       Impact factor: 2.257

4.  Progress toward a Respiratory Syncytial Virus Vaccine.

Authors:  Kathleen M Neuzil
Journal:  Clin Vaccine Immunol       Date:  2016-01-27

5.  A novel vaccine adjuvant based on straight polyacrylate potentiates vaccine-induced humoral and cellular immunity in cynomolgus macaques.

Authors:  Vincent Pavot; Hélène Bisceglia; Florine Guillaume; Sandrine Montano; Linong Zhang; Florence Boudet; Jean Haensler
Journal:  Hum Vaccin Immunother       Date:  2021-01-10       Impact factor: 3.452

6.  Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial.

Authors:  Tracy J Ruckwardt; Kaitlyn M Morabito; Emily Phung; Michelle C Crank; Pamela J Costner; LaSonji A Holman; Lauren A Chang; Somia P Hickman; Nina M Berkowitz; Ingelise J Gordon; Galina V Yamshchikov; Martin R Gaudinski; Bob Lin; Robert Bailer; Man Chen; Ana M Ortega-Villa; Thuy Nguyen; Azad Kumar; Richard M Schwartz; Lisa A Kueltzo; Judith A Stein; Kevin Carlton; Jason G Gall; Martha C Nason; John R Mascola; Grace Chen; Barney S Graham
Journal:  Lancet Respir Med       Date:  2021-04-14       Impact factor: 102.642

Review 7.  Respiratory syncytial virus infection: an innate perspective.

Authors:  Cecilia Johansson
Journal:  F1000Res       Date:  2016-12-21

8.  Effect of genetic background and delivery route on the preclinical properties of a live attenuated RSV vaccine.

Authors:  Rachel Groppo; Joshua DiNapoli; Kwang Il Jeong; Michael Kishko; Nicholas Jackson; Harold Kleanthous; Simon Delagrave; Linong Zhang; Mark Parrington
Journal:  PLoS One       Date:  2018-06-19       Impact factor: 3.240

9.  Respiratory syncytial virus elicits enriched CD8+ T lymphocyte responses in lung compared with blood in African green monkeys.

Authors:  Hualin Li; Cheryl Callahan; Michael Citron; Zhiyun Wen; Sinoeun Touch; Morgan A Monslow; Kara S Cox; Daniel J DiStefano; Kalpit A Vora; Andrew Bett; Amy Espeseth
Journal:  PLoS One       Date:  2017-11-09       Impact factor: 3.240

10.  Type I Interferon Potentiates IgA Immunity to Respiratory Syncytial Virus Infection During Infancy.

Authors:  Diego R Hijano; David T Siefker; Bishwas Shrestha; Sridhar Jaligama; Luan D Vu; Heather Tillman; David Finkelstein; Jordy Saravia; Dahui You; Stephania A Cormier
Journal:  Sci Rep       Date:  2018-07-23       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.